Recent Updates
Recently added Catalysts
AIDX Positive Sentiment

20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates

Key Takeaway: 20/20 BioLabs reported a 4.1% revenue increase to $1.36 million for the first nine months of 2026. The company secured a two-year cancer screening contract with Vermont, expected to boost revenue in Q4. However, third quarter revenue fell to $0.38 million, and net loss increased to $1.38 million, reflecting operational challenges.

Market Sentiment Analysis

POSITIVE FACTORS

  • OneTest™ revenue increased 4.1% to $1.36 million.
  • Gross margin expanded to 32.8% from 29.5%.
  • Vermont executed a two-year cancer screening contract.
  • Cash reserves increased to $3.63 million with no debt.

CONCERNS & RISKS

  • Third quarter revenue decreased to $0.38 million from $0.42 million.
  • Net loss widened to $1.38 million compared to $0.83 million last year.
  • Gross margin decreased to 25.5% due to lower testing volume.

Full Press Release Details

OneTest™ Revenue Increased 4.1% to $1.36 Million for First Nine Months of 2026, with Gross Margin Expanding to 32.8%
Vermont Executes Two-Year Firefighter Cancer Screening Contract with Testing Expected to Contribute Revenue in Q4
New Laboratory Franchise Model and 2027 Licensing Plans Aim to Broaden OneTest™ Distribution
Cash of $3.63 Million and No Outstanding Debt as of September 30, 2026
GAITHERSBURG, Md., Nov. 16, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reported its financial and operational results for the third quarter ended September 30, 2026.

Third Quarter and Recent Operational Highlights

• OneTest™ revenue increased 4.1% to $1.36 million for the first nine months of 2026, representing 92.8% of total revenue.
• OneTest™ gross profit increased 15.6% to $0.45 million for the first nine months of 2026, with gross margin expanding to 32.8% from 29.5%.
• Third quarter revenue was $0.38 million, compared to $0.42 million in the prior year period, reflecting the timing of firefighter cancer screening programs.
• Vermont executed a two-year contract specifying OneTest™ Premium for its statewide cancer screening program covering approximately 4,500 firefighters. Testing is expected to begin contributing to revenue in Q4 2026.
• Continued OneTest™ testing through Maryland's state-funded firefighter cancer screening program, with 18 groups of fire departments awarded more than $520,000 in grants.
• Introduced a OneTest™ laboratory franchise model to expand distribution through regional laboratories under a royalty-based structure.
• Announced plans to begin licensing its patented protein tumor marker testing technology to laboratories in the U.S. and internationally in 2027.
• Entered into $1.30 million of non-cancelable customer contracts during the first nine months of 2026.
• Cash and cash equivalents totaled $3.63 million as of September 30, 2026, with no outstanding borrowings.

Management Commentary

President and Chief Executive Officer Jonathan Cohen commented, “OneTest™ revenue grew 4.1% through the first nine months of the year, with gross profit increasing 15.6%. While third quarter revenue was below the prior year, much of this reflected the timing of our state-funded firefighter cancer screening programs. Maryland completed a significant portion of its testing in the second quarter, while the start of Vermont’s program shifted into the fourth quarter. Vermont has now executed its two-year contract, and we expect testing to begin contributing to revenue before year-end.”
“We are also working on new ways to reach more customers. Our franchise model would allow established regional laboratories to offer OneTest™ in their markets, without requiring us to build a national sales force. We have received preliminary interest from laboratories in the United States and plan to begin licensing our protein tumor marker approach to clinical laboratories in 2027.”
“With more than 25,000 firefighters screened to date, we are continuing to build the real-world evidence to support our regulatory strategy. We believe recent developments in the MCED testing industry are encouraging, and we remain focused on our goal of obtaining FDA authorization and Medicare reimbursement for OneTest™ for Cancer by the end of 2028,” concluded Cohen.
Chief Financial Officer Alan Bergman added, “We ended the third quarter with $3.63 million in cash and no outstanding borrowings, compared to $1.03 million in cash at year-end 2025. Our net loss narrowed to $1.38 million from $1.51 million in the second quarter, while operating expenses declined 4.0% sequentially.”
“Gross margin was lower this quarter due to reduced testing volume, but our laboratory has the capacity to support additional testing without a corresponding increase in certain operating costs. As testing under the Vermont contract and other programs increases, we expect to benefit from better utilization of our existing laboratory capacity while continuing to manage expenses,” concluded Bergman.

Third Quarter 2026 Financial Results

Total revenue for the three months ended September 30, 2026 was $0.38 million, compared to $0.42 million in the prior year period. OneTest™ revenue was $0.35 million, compared to $0.36 million, and represented 92.8% of total revenue, up from 86.3%. The decrease primarily reflected the timing of state-funded firefighter cancer screening programs.
Total cost of revenue was $0.28 million, compared to $0.27 million in the prior year period.
Gross profit was $0.10 million, compared to $0.15 million in the prior year period. Gross margin was 25.5%, compared to 34.7%, reflecting lower testing volume and the impact of fixed laboratory costs.
Operating expenses were $1.49 million, compared to $0.95 million in the prior year period and $1.55 million in Q2 2026. The year-over-year increase primarily reflected higher public company expenses.
Total other income, net, was $0.01 million, compared to other expense, net, of $0.03 million in the prior year period. The Company recorded no interest expense during the quarter.
Net loss was $1.38 million, compared to $0.83 million in the prior year period and $1.51 million in Q2 2026. Net loss included approximately $0.3 million in non-cash charges.
Cash and cash equivalents totaled $3.63 million as of September 30, 2026, compared to $1.03 million at year-end 2025, primarily reflecting $6.0 million in Series E preferred financing completed during the first half of 2026. The Company had no outstanding borrowings at quarter end.

First Nine Months 2026 Financial Results

Total revenue for the nine months ended September 30, 2026 was $1.46 million, compared to $1.51 million in the prior year period. OneTest™ revenue increased 4.1% to $1.36 million from $1.31 million, primarily driven by Maryland firefighter cancer screening programs.
Gross profit was $0.46 million, compared to $0.47 million in the prior year period. Gross margin was 31.7%, compared to 31.5%. OneTest™ gross profit increased 15.6% to $0.45 million, with gross margin expanding to 32.8% from 29.5%.
Total operating expenses were $4.54 million, compared to $2.89 million in the prior year period, primarily reflecting costs associated with the Company's transition to a Nasdaq-listed public company.
Net loss was $5.06 million, compared to $2.43 million in the prior year period. Net loss included approximately $2.0 million in non-cash charges and $0.98 million in other expense, net, primarily related to convertible notes converted or exchanged during the first half of 2026.

About 20/20 BioLabs

20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection blood test and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s tests are designed to be affordable and accessible and can be conveniently utilized at home using new, upper-arm capillary collection devices as an alternative to traditional venipuncture. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
For more information visit https://2020biolabs.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about our goals and strategies; our future business development, financial condition and results of operations; expected changes in our revenue, costs or expenditures; growth of and competition trends in our industry; our expectations regarding demand for, and market acceptance of, our products; our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with; fluctuations in general economic and business conditions in the market in which we operate; and relevant government policies and regulations relating to our industry.
In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Item 1A “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission, or the SEC, on March 31, 2026 and elsewhere in our filings with the SEC. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

Investor Relations Chris Tyson MZ Group Direct: 949-491-8235 AIDX@mzgroup.us

20/20 BIOLABS, INC. CONDENSED BALANCE SHEETS (UNAUDITED)
September 30, 2026 December 31, 2025
Assets
Current assets:
Cash and cash equivalents $ 3,633,711 $ 1,025,987
Accounts receivable, net 173,985 199,954
Inventory 102,568 116,217
Prepaid expenses and other current assets 119,525 128,975
Total current assets 4,029,789 1,471,133
License agreement, net 259,893 271,143
Property and equipment, net 24,525 56,677
Intangible asset, net 205,168 202,264
Right-of-use assets, net 475,670 605,289
Deferred financing costs - 1,507,794
Other assets 23,057 23,057
Total assets $ 5,018,102 $ 4,137,357
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable $ 1,045,819 $ 868,545
Accrued liabilities 642,335 785,784
Accrued dividends – Series E convertible preferred stock 128,441 -
Deferred revenue – current 478,937 414,871
Derivative liability – current - 143,382
Convertible notes payable – current - 74,611
Operating lease liability – current 195,848 175,948
Total current liabilities 2,491,380 2,463,141
Long-term liabilities:
Convertible notes payable, net - 619,355
Deferred revenue – long-term 29,372 41,816
Derivative liabilities – long-term - 543,545
Operating lease liability – long term 329,847 488,725
Total long-term liabilities 359,219 1,693,441
Total liabilities 2,850,599 4,156,582
Commitments and contingencies (Note 9) - -
Contingently redeemable convertible preferred stock:
Series E convertible preferred stock, $0.01 par value; 45,000 authorized; 5,015 and 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively; liquidation preference of $5,639,555 1,556,307 -
Stockholders’ equity (deficit):
Series D preferred stock, $0.01 par value; 936,329 authorized; 0 and 101,565 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively - 1,016
Series C preferred stock, $0.01 par value; 3,340,909 authorized; 0 and 1,204,040 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively - 12,040
Series B preferred stock, $0.01 par value; 3,569,405 authorized; 0 and 1,471,487 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively - 14,715
Series A-2 preferred stock, $0.01 par value; 800,000 authorized; 0 and 442,402 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively - 4,424
Series A-1 preferred stock, $0.01 par value; 978,000 authorized; 0 and 651,465 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively - 6,515
Series A preferred stock, $0.01 par value; 1,303,000 authorized; 0 and 846,368 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively - 8,464
Common stock, $0.01 par value; 500,000,000 and 50,000,000 authorized; 13,367,204 and 5,442,249 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively 133,672 54,422
Additional paid-in capital 38,781,013 33,126,398
Accumulated deficit (38,303,489 ) (33,247,219 )
Total stockholders’ equity (deficit) 611,196 (19,225 )
Total liabilities, contingently redeemable preferred stock and stockholders’ equity (deficit) $ 5,018,102 $ 4,137,357
20/20 BIOLABS, INC. CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Revenues $ 380,216 $ 417,979 $ 1,464,162 $ 1,506,859
Cost of revenues 283,343 272,913 999,678 1,032,735
Gross profit 96,873 145,066 464,484 474,124
Operating expenses:
Sales, general and administrative 1,363,385 814,179 4,007,461 2,430,134
Research and development 123,385 131,060 534,499 462,015
Total operating expenses 1,486,770 945,239 4,541,960 2,892,149
Operating loss (1,389,897 ) (800,173 ) (4,077,476 ) (2,418,025 )
Other (expense) income:
Interest expense - (29,547 ) (539,253 ) (31,222 )
Interest income 14,806 4,181 35,935 18,312
Loss on change in fair value of warrant liability - - (148,766 ) -
Loss on issuance of convertible note - - (326,595 ) -
Other expense, net - - (115 ) (115 )
Total other (expense) income 14,806 (25,366 ) (978,794 ) (13,025 )
Provision for income taxes - - - -
Net loss (1,375,091 ) (825,539 ) (5,056,270 ) (2,431,050 )
Deemed dividend on warrant modifications - - (1,124,676 ) -
Preferred stock dividends (128,441 ) - (304,295 ) -
Net loss attributable to common stockholders $ (1,503,532 ) $ (825,539 ) $ (6,485,241 ) $ (2,431,050 )
Basic and diluted net loss per common share $ (0.12 ) $ (0.17 ) $ (0.62 ) $ (0.50 )
Weighted-average common shares outstanding, basic and diluted 12,958,114 4,849,770 10,484,242 4,849,770
20/20 BIOLABS, INC. CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)
Nine Months Ended September 30,
2026 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (5,056,270 ) $ (2,431,050 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 34,601 48,743
Stock based compensation 710,137 388,950
Amortization of license fees 18,750 16,875
Issuance of common stock for services 283,595 -
Loss on issuance of convertible note 326,595 -
Amortization of right-of-use assets, net of liabilities (9,359 ) (5,516 )
Amortization of debt discount 515,583 17,238
Change in fair value of derivative liability 148,766 -
Changes in operating assets and liabilities:
Accounts receivable 25,969 (1,601 )
Inventory 13,649 (7,598 )
Prepaid expenses and other assets 9,450 (22,605 )
Accounts payable 254,847 256,081
Accrued liabilities (134,784 ) 250,109
Settlement liability - 80,000
Interest payable - 13,984
Deferred revenue 51,622 (11,663 )
Net cash used in operating activities (2,806,849 ) (1,408,053 )
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of intangible assets, including patents (5,354 ) -
License agreement (7,500 ) -
Net cash used in investing activities (12,854 ) -
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes payable 250,000 576,561
Proceeds from issuance of series D preferred stock - 192,338
Proceeds from issuance of series E convertible preferred stock 6,000,000 -
Offering costs (822,573 ) -
Net cash provided by financing activities 5,427,427 768,899
Increase (decrease) in cash and cash equivalents 2,607,724 (639,154 )
Cash and cash equivalents, beginning of period 1,025,987 1,784,009
Cash and cash equivalents, end of period $ 3,633,711 $ 1,144,855
Supplemental disclosures of cash flow information:
Cash paid for interest $ - $ -
Cash paid for income taxes $ - $ -
Non-cash disclosures of cash flow information:
Conversion of preferred stock to common stock $ 393,154 $ -
Deferred offering costs – issuance of common stock and warrants as offering costs $ 3,654,057 $ 452,736
Accrued dividends on series E convertible preferred stock $ 128,441 $ -
Relief of accounts payable through the issuance of common stock $ 77,574 $ -
Deemed dividend on warrant modifications $ 1,124,676 $ -
Issuance of preferred stock for dividends on series E convertible preferred stock $ 175,854 $ -
Derivative liabilities recognized as debt discounts $ 541,199 $ 152,384
Derivative liabilities reclassified to equity $ 1,381,124 $ -
Conversion of convertible notes payable and accrued interest to common stock $ 834,812 $ -
Conversion of convertible notes payable and accrued interest to series E convertible preferred stock $ 583,197 $ -

Frequently Asked Questions

What was 20/20 BioLabs' revenue for Q3 2026?

The revenue for Q3 2026 was $0.38 million.

How much did OneTest™ revenue increase in 2026?

OneTest™ revenue increased by 4.1% to $1.36 million.

What contract did Vermont execute with 20/20 BioLabs?

Vermont executed a two-year contract for firefighter cancer screening.

What was the net loss for 20/20 BioLabs in Q3 2026?

The net loss for Q3 2026 was $1.38 million.

Last updated: Nov 16, 2026